Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1092-9. doi: 10.1016/j.ijrobp.2013.12.050.

No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.

Author information

1
Carle Cancer Center and University of Illinois College of Medicine, Urbana, Illinois. Electronic address: sinisa.stanic@carle.com.
2
Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania.
3
University of Texas Southwestern, Dallas, Texas.
4
Washington University, St. Louis, Missouri.
5
Indiana University, Indianapolis, Indiana.
6
Princess Margaret Cancer Center, Toronto, Ontario, Canada.
7
Cleveland Clinic Foundation, Cleveland, Ohio.

Abstract

PURPOSE:

To investigate pulmonary function test (PFT) results and arterial blood gas changes (complete PFT) following stereotactic body radiation therapy (SBRT) and to see whether baseline PFT correlates with lung toxicity and overall survival in medically inoperable patients receiving SBRT for early stage, peripheral, non-small cell lung cancer (NSCLC).

METHODS AND MATERIALS:

During the 2-year follow-up, PFT data were collected for patients with T1-T2N0M0 peripheral NSCLC who received effectively 18 Gy × 3 in a phase 2 North American multicenter study (Radiation Therapy Oncology Group [RTOG] protocol 0236). Pulmonary toxicity was graded by using the RTOG SBRT pulmonary toxicity scale. Paired Wilcoxon signed rank test, logistic regression model, and Kaplan-Meier method were used for statistical analysis.

RESULTS:

At 2 years, mean percentage predicted forced expiratory volume in the first second and diffusing capacity for carbon monoxide declines were 5.8% and 6.3%, respectively, with minimal changes in arterial blood gases and no significant decline in oxygen saturation. Baseline PFT was not predictive of any pulmonary toxicity following SBRT. Whole-lung V5 (the percentage of normal lung tissue receiving 5 Gy), V10, V20, and mean dose to the whole lung were almost identical between patients who developed pneumonitis and patients who were pneumonitis-free. Poor baseline PFT did not predict decreased overall survival. Patients with poor baseline PFT as the reason for medical inoperability had higher median and overall survival rates than patients with normal baseline PFT values but with cardiac morbidity.

CONCLUSIONS:

Poor baseline PFT did not appear to predict pulmonary toxicity or decreased overall survival after SBRT in this medically inoperable population. Poor baseline PFT alone should not be used to exclude patients with early stage lung cancer from treatment with SBRT.

PMID:
24661663
PMCID:
PMC4058437
DOI:
10.1016/j.ijrobp.2013.12.050
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center